A detailed history of Geode Capital Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,060,131 shares of HALO stock, worth $140 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,060,131
Previous 3,029,230 1.02%
Holding current value
$140 Million
Previous $159 Million 10.38%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $1.59 Million - $1.99 Million
30,901 Added 1.02%
3,060,131 $175 Million
Q2 2024

Aug 09, 2024

BUY
$37.81 - $52.4 $69,797 - $96,730
1,846 Added 0.06%
3,029,230 $159 Million
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $3.62 Million - $4.51 Million
107,621 Added 3.69%
3,027,384 $123 Million
Q4 2023

Feb 13, 2024

BUY
$33.32 - $42.1 $4.41 Million - $5.57 Million
132,414 Added 4.75%
2,919,763 $108 Million
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $2.08 Million - $2.51 Million
57,081 Added 2.09%
2,787,349 $106 Million
Q2 2023

Aug 11, 2023

BUY
$30.28 - $38.74 $2.99 Million - $3.83 Million
98,881 Added 3.76%
2,730,268 $98.5 Million
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $3.82 Million - $6.48 Million
116,290 Added 4.62%
2,631,387 $100 Million
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $1.53 Million - $2.27 Million
38,233 Added 1.54%
2,515,097 $143 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $1.32 Million - $1.77 Million
34,166 Added 1.4%
2,476,864 $97.9 Million
Q2 2022

Aug 12, 2022

SELL
$37.35 - $48.3 $2.38 Million - $3.08 Million
-63,836 Reduced 2.55%
2,442,698 $107 Million
Q1 2022

May 13, 2022

BUY
$31.97 - $41.06 $1.02 Million - $1.31 Million
31,968 Added 1.29%
2,506,534 $100 Million
Q4 2021

Feb 11, 2022

BUY
$31.82 - $40.75 $496,169 - $635,414
15,593 Added 0.63%
2,474,566 $99.5 Million
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $475,142 - $573,333
12,351 Added 0.5%
2,458,973 $100 Million
Q2 2021

Aug 13, 2021

BUY
$38.84 - $51.31 $6.97 Million - $9.2 Million
179,364 Added 7.91%
2,446,622 $111 Million
Q1 2021

May 12, 2021

BUY
$39.51 - $51.45 $5.51 Million - $7.18 Million
139,458 Added 6.55%
2,267,258 $94.5 Million
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $2.19 Million - $3.7 Million
84,776 Added 4.15%
2,127,800 $90.9 Million
Q3 2020

Nov 13, 2020

BUY
$25.74 - $29.63 $3.42 Million - $3.93 Million
132,683 Added 6.95%
2,043,024 $53.7 Million
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $436,036 - $719,392
26,833 Added 1.42%
1,910,341 $51.2 Million
Q1 2020

May 14, 2020

SELL
$13.9 - $21.83 $18,417 - $28,924
-1,325 Reduced 0.07%
1,883,508 $33.9 Million
Q4 2019

Feb 13, 2020

BUY
$14.93 - $19.53 $900,771 - $1.18 Million
60,333 Added 3.31%
1,884,833 $33.4 Million
Q3 2019

Nov 12, 2019

SELL
$15.2 - $17.69 $141,937 - $165,189
-9,338 Reduced 0.51%
1,824,500 $28.3 Million
Q2 2019

Aug 14, 2019

BUY
$14.75 - $17.26 $2.74 Million - $3.2 Million
185,483 Added 11.25%
1,833,838 $31.5 Million
Q1 2019

May 14, 2019

BUY
$13.94 - $17.58 $1.78 Million - $2.24 Million
127,698 Added 8.4%
1,648,355 $26.5 Million
Q4 2018

Feb 13, 2019

BUY
$13.33 - $18.66 $1.02 Million - $1.43 Million
76,753 Added 5.32%
1,520,657 $22.2 Million
Q3 2018

Nov 13, 2018

BUY
$16.68 - $18.41 $675,256 - $745,292
40,483 Added 2.88%
1,443,904 $26.2 Million
Q2 2018

Aug 14, 2018

BUY
$16.87 - $20.3 $2.18 Million - $2.63 Million
129,403 Added 10.16%
1,403,421 $23.7 Million
Q1 2018

May 15, 2018

BUY
$17.06 - $21.2 $389,940 - $484,568
22,857 Added 1.83%
1,274,018 $25 Million
Q4 2017

Feb 13, 2018

BUY
$16.75 - $20.8 $1.64 Million - $2.04 Million
98,045 Added 8.5%
1,251,161 $25.3 Million
Q3 2017

Nov 14, 2017

SELL
$11.76 - $17.4 $31,552 - $46,684
-2,683 Reduced 0.23%
1,153,116 $20 Million
Q2 2017

Aug 14, 2017

BUY
N/A
1,155,799
1,155,799 $14.8 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.